Clinical trial
Open-Label, Multi-Center Study of SR29142 as Uricolytic Therapy/Prophylaxis for Hyperuricemia in Pediatric Patients With Newly Diagnosed Hematological Malignancies at High Risk for Tumor Lysis Syndrome
NCT00290992 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Open-Label, Multi-Center Study of SR29142 as Uricolytic Therapy/Prophylaxis for Hyperuricemia in Pediatric Patients With Newly Diagnosed Hematological Malignancies at High Risk for Tumor Lysis Syndrome
- Lead sponsor
- Sanofi
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 30, 2005
- Completion date
- April 30, 2006
- Enrollment
- 30 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.